• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Predicting treatment effect for non-squamous non-small cell lung cancer

Research Project

Project/Area Number 17K09620
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Respiratory organ internal medicine
Research InstitutionYokohama City University

Principal Investigator

Horita Nobuyuki  横浜市立大学, 医学研究科, 客員講師 (50616448)

Co-Investigator(Kenkyū-buntansha) 金子 猛  横浜市立大学, 医学研究科, 教授 (90275066)
原 悠  横浜市立大学, 医学部, 講師 (70806299)
Project Period (FY) 2017-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Keywords肺癌 / タンパク質
Outline of Final Research Achievements

According to our analysis with 16,141 NSCLC cases, CBDCA+Paclitaxel+BEV, CBDCA+PEM+BEV, CDDP+PEM, CBDCA+PEM, and CDGP+DTX contributed to the prolonged OS. Sub-population analysis with 285 elderly cases, CBDCA+PEM was effective and resulted in OS of 14.9 months. Proteomics analysis suggested 15 proteins were related to the life prognosis of NSCLC patients.

Academic Significance and Societal Importance of the Research Achievements

特定されたバイオマーカーで殺細胞性抗癌剤の非扁平上皮非小細胞肺癌に対する治療効果を予想することができ、殺細胞性抗癌剤投与適応の判断材料の一つとなり、現在注目されている個別化医療(オーダーメイド医療)を更に推進できる。個々の患者に対する治療選択根拠を提案でき、近年問題となっている高額な肺癌抗癌剤による医療経済的問題にも寄与できる。将来的には新たな治療標的となる可能性があり、将来の創薬に寄与できる可能性がある。

Report

(4 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (3 results)

All 2019 2017

All Journal Article (3 results) (of which Peer Reviewed: 3 results,  Open Access: 1 results)

  • [Journal Article] Carboplatin plus pemetrexed for the elderly incurable chemo-naive nonsquamous non-small cell lung cancer: Meta-analysis.2019

    • Author(s)
      Ito M, Horita N, Nagashima A, Kaneko T
    • Journal Title

      Asia Pac J Clin Oncol.

      Volume: 15 Issue: 2

    • DOI

      10.1111/ajco.12837

    • Related Report
      2019 Annual Research Report 2018 Research-status Report 2017 Research-status Report
    • Peer Reviewed
  • [Journal Article] The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.2019

    • Author(s)
      Ito K, Miura S, Sakaguchi T, Murotani K, Horita N, Akamatsu H, Uemura K, Morita S, Yamamoto N.
    • Journal Title

      Lung Cancer

      Volume: 128 Pages: 113-119

    • DOI

      10.1016/j.lungcan.2018.12.023

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.2017

    • Author(s)
      Horita N, Nagashima A, Nakashima K, Shibata Y, Ito K, Goto A, Yamanaka T, Kaneko T.
    • Journal Title

      Sci Rep

      Volume: 7 Issue: 1 Pages: 13185-13185

    • DOI

      10.1038/s41598-017-13724-2

    • Related Report
      2017 Research-status Report
    • Peer Reviewed / Open Access

URL: 

Published: 2017-04-28   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi